Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Poxel
Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.

At the end of 2018, the group had a portfolio of 3 products in clinical development, including 1 in Phase III (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 2 in phase II (PXL770 and PXL065, for the treatment of glucose and lipid irregularities).
Sales per Businesses
20172018Delta
EUR (in Million)%EUR (in Million)%
Innovating Molecules5.29100%74.61100% +1310.26%
Sales per Regions
20172018Delta
EUR (in Million)%EUR (in Million)%
France5.29100%74.61100% +1310.26%
Managers
NameAgeSinceTitle
Thomas Kuhn442009Chief Executive Officer & Director
Pierre Legault582016Chairman
Anne Renevot-2017Chief Financial Officer
Sophie Hallakou-Bozec, Dr.-2009Senior Vice Chairman-Research & Development
Takashi Kaneko, Dr.--Vice President-Medical
Mohammed Khoso Baluch602013Independent Director
Thierry Hercend, Dr.-2016Director
Richard N. Kender622015Independent Director
Pascale Boissel512015Independent Director
Janice Bourque612016Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 25,914,777 16,223,316 62.6% 0 0.0% 62.6%
Shareholders
NameEquities%
Andera Partners SCA 4,162,716 16.1%
BPIFrance Investissement SAS 2,174,354 8.40%
Bpifrance Participations SA /PRIVATE EQUITY/ 2,054,758 7.94%
Thomas Kuhn 1,506,740 5.82%
Roivant Sciences Ltd. 1,431,399 5.53%
Deuterx LLC 1,290,000 4.98%
JPMorgan Asset Management (UK) Ltd. 1,012,296 3.91%
Federated Global Investment Management Corp. 664,641 2.57%
Bellevue Asset Management AG 216,866 0.84%
CPR Asset Management SA 182,774 0.71%
Holdings
NameEquities%Valuation
Poxel (POXEL) 38,1000.15%326,023 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Euronext Paris
- Compartiment B
- CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  POXEL:FR
- Reuters Code :  POXEL.PA
- Datastream Code :  
Company contact information
Poxel
Immeuble Le Sunway 259/261 Avenue Jean Jaurès
FR-69007 Lyon
France

Phone : +33 (0)4 37 37 20 10
Fax : +33 (0)4 37 70 88 15
Internet : http://www.poxel.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Poxel
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
POXEL47.35%214
GILEAD SCIENCES7.24%84 866
VERTEX PHARMACEUTICALS34.72%57 409
REGENERON PHARMACEUTICALS-0.33%40 697
WUXI APPTEC CO., LTD.74.02%21 510
GENMAB51.29%15 541
BEIGENE, LTD.33.27%11 427
NEUROCRINE BIOSCIENCES, INC.63.58%10 757
SAREPTA THERAPEUTICS, INC.0.30%8 159
AMARIN CORPORATION PLC64.95%8 057
ARROWHEAD PHARMACEUTICALS, INC.441.63%6 707
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 661
REATA PHARMACEUTICALS, INC.255.29%6 512
ARGENX SE57.28%6 326
PEPTIDREAM INC.20.28%5 872
EXELIXIS, INC.-11.74%5 275
ASCENDIS PHARMA A/S71.68%5 135
BIOCON LIMITED-8.12%4 796
CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.54.06%4 496
BLUEBIRD BIO, INC.-19.94%4 394
SPARK THERAPEUTICS, INC.182.70%4 263